Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol
Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol
INTRODUCTION: Parenteral anticoagulants may improve outcomes in patients with cancer by reducing risk of venous thromboembolic disease and through a direct antitumour effect. Study-level systematic reviews indicate a reduction in venous thromboembolism and provide moderate confidence that a small survival benefit exists. It remains unclear if any patient subgroups experience potential benefits.
METHODS AND ANALYSIS: First, we will perform a comprehensive systematic search of MEDLINE, EMBASE and The Cochrane Library, hand search scientific conference abstracts and check clinical trials registries for randomised control trials of participants with solid cancers who are administered parenteral anticoagulants. We anticipate identifying at least 15 trials, exceeding 9000 participants. Second, we will perform an individual participant data meta-analysis to explore the magnitude of survival benefit and address whether subgroups of patients are more likely to benefit from parenteral anticoagulants. All analyses will follow the intention-to-treat principle. For our primary outcome, mortality, we will use multivariable hierarchical models with patient-level variables as fixed effects and a categorical trial variable as a random effect. We will adjust analysis for important prognostic characteristics. To investigate whether intervention effects vary by predefined subgroups of patients, we will test interaction terms in the statistical model. Furthermore, we will develop a risk-prediction model for venous thromboembolism, with a focus on control patients of randomised trials.
ETHICS AND DISSEMINATION: Aside from maintaining participant anonymity, there are no major ethical concerns. This will be the first individual participant data meta-analysis addressing heparin use among patients with cancer and will directly influence recommendations in clinical practice guidelines. Major cancer guideline development organisations will use eventual results to inform their guideline recommendations. Several knowledge users will disseminate results through presentations at clinical rounds as well as national and international conferences. We will prepare an evidence brief and facilitate dialogue to engage policymakers and stakeholders in acting on findings.
TRIAL REGISTRATION NUMBER: PROSPERO CRD42013003526.
Anticoagulants, Drug Administration Schedule, Heparin, Humans, Neoplasms, Patient Selection, Practice Guidelines as Topic, Prognosis, Quality of Life, Randomized Controlled Trials as Topic, Survival Analysis, Venous Thromboembolism, Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review
1-11
Schünemann, Holger J.
d57a9844-6cfe-475f-b4a8-fd89104fee4c
Ventresca, Matthew
81f45dfd-e1bc-46ec-87a2-d52cca354b90
Crowther, Mark
9eea6edf-dc0e-4ab5-bf67-54dad735d184
Briel, Matthias
deba5c1d-6a6e-426e-a132-05cec40ecbce
Zhou, Qi
8601b338-541d-416e-ae6d-7c5b9230dc1e
Garcia, David
453fb1b2-f557-45cc-8acb-894d0cde0220
Lyman, Gary
4727c4cc-f21d-4b2b-a1cf-f32cd607ac39
Noble, Simon
be42d512-f03e-41bc-a1ab-c12dbf249836
Macbeth, Fergus
e4ea3d86-4ce3-402f-bfbd-1bcb4bdfebb2
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
DiNisio, Marcello
a5ae8e1f-cee8-4237-aab1-d46cc7063dfe
Iorio, Alfonso
32c59f2e-f026-469e-bea2-4d44b35ae1bd
Beyene, Joseph
c2f82336-3797-413d-87d6-585a84f371f1
Mbuagbaw, Lawrance
6abe7291-4a68-41e6-ae7f-c05fe265c935
Neumann, Ignacio
a85e3802-8408-485b-ab02-ca947c55e182
Van Es, Nick
9dd6b7d5-fb70-490e-89bd-1c7e7534a68e
Brouwers, Melissa
99813f8b-0f07-4ce9-8b60-30c96765b55b
Brozek, Jan
9735286c-65cd-4661-bb6c-c01a7b7b3573
Guyatt, Gordon
9441513c-987a-497c-8103-a70f3e1d623c
Levine, Mark
e48d2706-a296-4f83-bd41-7425b01ca699
Moll, Stephan
f4cbe6bd-986c-413c-8db0-141faa27bc2b
Santesso, Nancy
863cb231-7f2c-4be7-a2c0-101cd043a7e8
Streiff, Michael
9d29ff82-b50b-4c27-93da-4954b2e17166
Baldeh, Tejan
6e228a58-1a2d-4f77-8ea1-841e7ae787cf
Florez, Ivan
f6a3243d-cea2-410e-bf5e-2785efb22671
Gurunlu Alma, Ozlem
82f9977c-fad2-48ff-bc98-ca387d65c704
Solh, Ziad
b55cbd2b-cb1a-4c81-a47e-75555f27e451
Ageno, Walter
90b53814-7ece-49b3-a57e-f44e1b680892
Marcucci, Maura
fbaaa8b6-a349-4cbb-acd8-2a9088b4621a
Bozas, George
f46bca33-3267-45f3-89b6-03e3731f2ce4
Zulian, Gilbert
8d3392db-135e-407d-a17b-36fc3174fff0
Maraveyas, Anthony
d3b63674-d174-461a-b4d3-c561f9666440
Lebeau, Bernard
ef267c9d-7ebd-47be-8089-ec6f8913811c
Buller, Harry
bc3be66d-690a-4727-b1f6-febda4ab476c
Evans, Jessica
7db17efc-8cd6-4d56-8d43-8239616804ba
McBane, Robert
71f9c634-0127-4e53-a2c5-214daace5186
Bleker, Suzanne
742acc64-1f95-47e0-bdfc-f1986ffb7602
Pelzer, Uwe
d2a58911-7cc7-43e4-90de-99fe921f0fdb
Akl, Elie A.
2780319d-c583-4f1a-a09d-ead8fa7228da
IPDMA heparin use in cancer patients research group
April 2016
Schünemann, Holger J.
d57a9844-6cfe-475f-b4a8-fd89104fee4c
Ventresca, Matthew
81f45dfd-e1bc-46ec-87a2-d52cca354b90
Crowther, Mark
9eea6edf-dc0e-4ab5-bf67-54dad735d184
Briel, Matthias
deba5c1d-6a6e-426e-a132-05cec40ecbce
Zhou, Qi
8601b338-541d-416e-ae6d-7c5b9230dc1e
Garcia, David
453fb1b2-f557-45cc-8acb-894d0cde0220
Lyman, Gary
4727c4cc-f21d-4b2b-a1cf-f32cd607ac39
Noble, Simon
be42d512-f03e-41bc-a1ab-c12dbf249836
Macbeth, Fergus
e4ea3d86-4ce3-402f-bfbd-1bcb4bdfebb2
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
DiNisio, Marcello
a5ae8e1f-cee8-4237-aab1-d46cc7063dfe
Iorio, Alfonso
32c59f2e-f026-469e-bea2-4d44b35ae1bd
Beyene, Joseph
c2f82336-3797-413d-87d6-585a84f371f1
Mbuagbaw, Lawrance
6abe7291-4a68-41e6-ae7f-c05fe265c935
Neumann, Ignacio
a85e3802-8408-485b-ab02-ca947c55e182
Van Es, Nick
9dd6b7d5-fb70-490e-89bd-1c7e7534a68e
Brouwers, Melissa
99813f8b-0f07-4ce9-8b60-30c96765b55b
Brozek, Jan
9735286c-65cd-4661-bb6c-c01a7b7b3573
Guyatt, Gordon
9441513c-987a-497c-8103-a70f3e1d623c
Levine, Mark
e48d2706-a296-4f83-bd41-7425b01ca699
Moll, Stephan
f4cbe6bd-986c-413c-8db0-141faa27bc2b
Santesso, Nancy
863cb231-7f2c-4be7-a2c0-101cd043a7e8
Streiff, Michael
9d29ff82-b50b-4c27-93da-4954b2e17166
Baldeh, Tejan
6e228a58-1a2d-4f77-8ea1-841e7ae787cf
Florez, Ivan
f6a3243d-cea2-410e-bf5e-2785efb22671
Gurunlu Alma, Ozlem
82f9977c-fad2-48ff-bc98-ca387d65c704
Solh, Ziad
b55cbd2b-cb1a-4c81-a47e-75555f27e451
Ageno, Walter
90b53814-7ece-49b3-a57e-f44e1b680892
Marcucci, Maura
fbaaa8b6-a349-4cbb-acd8-2a9088b4621a
Bozas, George
f46bca33-3267-45f3-89b6-03e3731f2ce4
Zulian, Gilbert
8d3392db-135e-407d-a17b-36fc3174fff0
Maraveyas, Anthony
d3b63674-d174-461a-b4d3-c561f9666440
Lebeau, Bernard
ef267c9d-7ebd-47be-8089-ec6f8913811c
Buller, Harry
bc3be66d-690a-4727-b1f6-febda4ab476c
Evans, Jessica
7db17efc-8cd6-4d56-8d43-8239616804ba
McBane, Robert
71f9c634-0127-4e53-a2c5-214daace5186
Bleker, Suzanne
742acc64-1f95-47e0-bdfc-f1986ffb7602
Pelzer, Uwe
d2a58911-7cc7-43e4-90de-99fe921f0fdb
Akl, Elie A.
2780319d-c583-4f1a-a09d-ead8fa7228da